San Rafael, California; Canadian Solar Inc. of Kitchener, Ontario, Canada; and Canadian Solar (USA) Inc. of San Ramon, California. *Id.*

On May 25, 2012, all of the private parties filed a joint motion to terminate the investigation based on confidential settlement agreements under Commission rules 210.21(a)(2) and (b). The Commission investigative attorney supported the motion.

On June 13, 2012, the presiding ALJ issued an ID (Order No. 11) granting the joint motion. No party petitioned for review of the ID.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in section 210.42(h) of the Commission's Rules of Practice and Procedure, 19 CFR 210.42(h).

By order of the Commission.

Issued: June 29, 2012.

**Lisa R. Barton,**

*Acting Secretary to the Commission.*

[FR Doc. 2012–16433 Filed 7–3–12; 8:45 am]

**BILLING CODE 7020–02–P**

## DEPARTMENT OF JUSTICE

### Notice of Lodging of Proposed Consent Decree With Dairyland Power Cooperative Under the Clean Air Act

Pursuant to 28 CFR 50.7, notice is hereby given that on June 28, 2012, a proposed Consent Decree in *United States of America* v. *Dairyland Power Cooperative (''Dairyland''),* Civil Action No. 12-cv-462, was lodged with the United States District Court for the Western District of Wisconsin.

In this civil enforcement action under the federal Clean Air Act (''Act''), the United States alleges that Dairyland—an electric utility—failed to comply with certain requirements of the Act intended to protect air quality. The complaint alleges that Dairyland violated the Prevention of Significant Deterioration (''PSD'') and Title V provisions of the Act, 42 U.S.C. 7401–7671 *et seq.,* and related state and federal implementing regulations, at the Alma/J.P. Madgett Generating Station, a coal-fired power plant in Buffalo County, Wisconsin, and the Genoa Generating Station, a coal-fired power plant in Vernon County, Wisconsin. The alleged violations arise from the construction of modifications at the power plants and operation of the plants in violation of PSD and Title V requirements. The complaint alleges that Dairyland failed to obtain appropriate permits and failed to install and apply required pollution control devices to reduce emissions of various air pollutants. The complaint seeks both injunctive relief and civil penalties.

The proposed Decree lodged with the Court requires installation and operation of certain pollution control devices at the Alma/J.P. Madgett and Genoa plants, and the permanent cessation of operations of certain units at the Alma/J.P. Madgett plant. The settlement will reduce emissions of sulfur dioxide (''$SO_2$''), nitrogen oxides (''$NO_X$''), and particular matter (''PM'') through emission control requirements and limitations specified by the proposed Decree. Dairyland will also fund environmental projects at a cost of at least $5 million to mitigate the alleged adverse effects of its past violations, and will pay a civil penalty of $950,000.

The Department of Justice will receive for a period of thirty (30) days from the date of this publication comments relating to the Consent Decree. Comments should be addressed to the Assistant Attorney General, Environment and Natural Resources Division, and either emailed to *pubcomment-ees.enrd@usdoj.gov* or mailed to P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611, and should refer to *United States* v. *Dairyland Power Cooperative,* D.J. Ref. 90–5–2–1–10163.

During the public comment period, the Consent Decree may also be examined on the following Department of Justice Web site, *http://www.usdoj.gov/enrd/Consent_Decrees.html.* A copy of the Consent Decree may also be obtained by mail from the Consent Decree Library, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611 or by faxing or emailing a request to ''Consent Decree Copy'' (*EESCDCopy.ENRD@usdoj.gov*), fax no. (202) 514–0097, phone confirmation number (202) 514–5271. If requesting a copy from the Consent Decree Library by mail, please enclose a check in the amount of $24.25 (25 cents per page reproduction cost) payable to the U.S. Treasury or, if requesting by email or fax, forward a check in that amount to the Consent Decree Library at the address given above.

**Maureen Katz,**

*Assistant Chief, Environmental Enforcement Section, Environment and Natural Resources Division.*

[FR Doc. 2012–16353 Filed 7–3–12; 8:45 am]

**BILLING CODE 4410–15–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

**[Docket No. DEA–363]**

### Controlled Substances: Proposed Adjustment to the Aggregate Production Quotas for 2012

**AGENCY:** Drug Enforcement Administration (DEA), Department of Justice.

**ACTION:** Notice with request for comments.

**SUMMARY:** This notice proposes to adjust the 2012 aggregate production quotas for several controlled substances in schedules I and II of the Controlled Substances Act (CSA).

**DATES:** Electronic comments must be submitted and written comments must be postmarked on or before August 6, 2012. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after midnight Eastern Time on the last day of the comment period.

**ADDRESSES:** To ensure proper handling of comments, please reference ''Docket No. DEA–363'' on all electronic and written correspondence. DEA encourages all comments be submitted electronically through *http://www.regulations.gov* using the electronic comment form provided on that site. An electronic copy of this document is also available at the *http://www.regulations.gov* Web site for easy reference. Paper comments that duplicate the electronic submission are not necessary as all comments submitted to *www.regulations.gov* will be posted for public review and are part of the official docket record. Should you, however, wish to submit written comments via regular or express mail, they should be sent to the Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODL, 8701 Morrissette Drive, Springfield, VA 22152.

**FOR FURTHER INFORMATION CONTACT:** John W. Partridge, Chief, Liaison and Policy Section, Drug Enforcement Administration, 8701 Morrissette Drive, Springfield, VA 22152, Telephone: (202) 307–4654.

**SUPPLEMENTARY INFORMATION:**

#### Posting of Public Comments

Please note that all comments received are considered part of the public record and made available for public inspection online at *http://www.regulations.gov* and in the DEA's public docket. Such information includes personal identifying

information (such as your name, address, etc.) voluntarily submitted by the commenter.

If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase ''PERSONAL IDENTIFYING INFORMATION'' in the first paragraph of your comment. You must also place all the personal identifying information you do not want posted online or made available in the public docket in the first paragraph of your comment and identify what information you want redacted.

If you want to submit confidential business information as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase ''CONFIDENTIAL BUSINESS INFORMATION'' in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment. If a comment has so much confidential business information that it cannot be effectively redacted, all or part of that comment may not be posted online or made available in the public docket.

Personal identifying information and confidential business information identified and located as set forth above will be redacted, and the comment, in redacted form, will be posted online and placed in the DEA's public docket file. Please note that the Freedom of Information Act applies to all comments received. If you wish to inspect the agency's public docket file in person by appointment, please see the **FOR FURTHER INFORMATION CONTACT** paragraph.

## Background

Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General establish aggregate production quotas for each basic class of controlled substance listed in schedules I and II. This responsibility has been delegated to the Administrator of the DEA by 28 CFR 0.100. The Administrator, in turn, has redelegated this function to the Deputy Administrator, pursuant to 28 CFR 0.104. The 2012 established aggregate production quotas for controlled substances in schedules I and II were published in the **Federal Register** (76 FR 78044) on December 15, 2011. That notice stipulated that, as provided for in 21 CFR 1303.13, all aggregate production quotas are subject to adjustment.

## Analysis for Proposed Revised 2012 Aggregate Production Quotas

DEA now proposes to adjust the established 2012 aggregate production quotas for some schedule I and II controlled substances. In proposing the adjustment, DEA has taken into account the criteria that DEA is required to consider in accordance with 21 CFR 1303.13. DEA proposes the adjustment of the aggregate production quotas for basic classes of schedule I and II controlled substances by considering (1) Changes in demand for the class, changes in the national rate of net disposal for the class, and changes in the rate of net disposal by the registrants holding individual manufacturing quotas for the class; (2) whether any increased demand or changes in the national and/or individual rates of net disposal are temporary, short term, or long term; (3) whether any increased demand can be met through existing inventories, increased individual manufacturing quotas, or increased importation without increasing the aggregate production quota; (4) whether any decreased demand will result in excessive inventory accumulation by all persons registered to handle the class; and (5) other factors affecting the medical, scientific, research, and industrial needs of the United States and lawful export requirements, as the Administrator finds relevant.

In determining whether to propose adjustments to the 2012 aggregate production quotas, DEA considered updated information obtained from 2011 year-end inventories, 2011 disposition data submitted by quota applicants, estimates of the medical needs of the United States, product development, and other information made available to DEA after the initial aggregate production quotas had been established. The Deputy Administrator, therefore, proposes to adjust the 2012 aggregate production quotas for some schedule I and II controlled substances, expressed in grams of anhydrous acid or base, as follows:

| Basic class | Previously established 2012 quotas | Proposed adjusted 2012 quotas |
|---|---|---|
| **Schedule I** | | |
| 1-[1-(2-Thienyl)cyclohexyl]piperidine | 0 g | 5 g. |
| 1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200) | 45 g | No Change. |
| 1-Butyl-3-(1-naphthoyl)indole (JWH-073) | 45 g | No Change. |
| 1-Methyl-4-phenyl-4-propionoxypiperidine | 2 g | No Change. |
| 1-Pentyl-3-(1-naphthoyl)indole (JWH-018) | 45 g | No Change. |
| 2,5-Dimethoxyamphetamine | 2 g | 12 g. |
| 2,5-Dimethoxy-4-ethylamphetamine (DOET) | 2 g | 12 g. |
| 2,5-Dimethoxy-4-n-propylthiophenethylamine | 2 g | 12 g. |
| 3-Methylfentanyl | 2 g | No Change. |
| 3-Methylthiofentanyl | 2 g | No Change. |
| 3,4-Methylenedioxyamphetamine (MDA) | 22 g | 30 g. |
| 3,4-Methylenedioxy-N-methylcathinone (methylone) | 8 g | 12 g. |
| 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) | 15 g | 24 g. |
| 3,4-Methylenedioxymethamphetamine (MDMA) | 22 g | 30 g. |
| 3,4-Methylenedioxypyrovalerone (MDPV) | 8 g | 12 g. |
| 3,4,5-Trimethoxyamphetamine | 2 g | 12 g. |
| 4-Bromo-2,5-dimethoxyamphetamine (DOB) | 2 g | 12 g. |
| 4-Bromo-2,5-dimethoxyphenethylamine (2-CB) | 2 g | 12 g. |
| 4-Methoxyamphetamine | 77 g | 88 g. |
| 4-Methylaminorex | 2 g | 12 g. |
| 4-Methyl-2,5-dimethoxyamphetamine (DOM) | 2 g | 12 g. |
| 4-Methyl-N-methylcathinone (mephedrone) | 8 g | 12 g. |
| 5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol | 68 g | No Change. |
| 5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol | 53 g | No Change. |

| Basic class | Previously established 2012 quotas | Proposed adjusted 2012 quotas |
|---|---|---|
| 5-Methoxy-3,4-methylenedioxyamphetamine | 2 g | 12 g. |
| 5-Methoxy-N,N-diisopropyltryptamine | 2 g | 12 g. |
| Acetyl-alpha-methylfentanyl | 2 g | No Change. |
| Acetyldihydrocodeine | 2 g | No Change. |
| Acetylmethadol | 2 g | No Change. |
| Allylprodine | 2 g | No Change. |
| Alphacetylmethadol | 2 g | No Change. |
| Alpha-ethyltryptamine | 2 g | 12 g. |
| Alphameprodine | 2 g | No Change. |
| Alphamethadol | 2 g | No Change. |
| Alpha-methylfentanyl | 2 g | No Change. |
| Alpha-methylthiofentanyl | 2 g | No Change. |
| Alpha-methyltryptamine (AMT) | 2 g | 12 g. |
| Aminorex | 2 g | 12 g. |
| Benzylmorphine | 2 g | No Change. |
| Betacetylmethadol | 2 g | No Change. |
| Beta-hydroxy-3-methylfentanyl | 2 g | No Change. |
| Beta-hydroxyfentanyl | 2 g | No Change. |
| Betameprodine | 2 g | No Change. |
| Betamethadol | 2 g | No Change. |
| Betaprodine | 2 g | No Change. |
| Bufotenine | 3 g | No Change. |
| Cathinone | 4 g | 12 g. |
| Codeine-N-oxide | 602 g | No Change. |
| Diethyltryptamine | 2 g | 12 g. |
| Difenoxin | 50 g | No Change. |
| Dihydromorphine | 3,608,000 g | No Change. |
| Dimethyltryptamine | 7 g | 18 g. |
| Gamma-hydroxybutyric acid | 47,000,000 g | No Change. |
| Heroin | 20 g | No Change. |
| Hydromorphinol | 54 g | No Change. |
| Hydroxypethidine | 2 g | No Change. |
| Ibogaine | 5 g | No Change. |
| Lysergic acid diethylamide (LSD) | 16 g | No Change. |
| Marihuana | 21,000 g | No Change. |
| Mescaline | 5 g | 13 g. |
| Methaqualone | 10 g | No Change. |
| Methcathinone | 4 g | 12 g. |
| Methyldihydromorphine | 2 g | No Change. |
| Morphine-N-oxide | 655 g | No Change. |
| N-Benzylpiperazine | 2 g | 12 g. |
| N,N-Dimethylamphetamine | 2 g | 12 g. |
| N-Ethylamphetamine | 2 g | 12 g. |
| N-Hydroxy-3,4-methylenedioxyamphetamine | 2 g | 12 g. |
| Noracymethadol | 2 g | No Change. |
| Norlevorphanol | 52 g | No Change. |
| Normethadone | 2 g | No Change. |
| Normorphine | 18 g | No Change. |
| Para-fluorofentanyl | 2 g | No Change. |
| Phenomorphan | 2 g | No Change. |
| Pholcodine | 2 g | No Change. |
| Properidine | 2 g | No Change. |
| Psilocybin | 2 g | No Change. |
| Psilocyn | 2 g | No Change. |
| Tetrahydrocannabinols | 393,000 g | No Change. |
| Thiofentanyl | 2 g | No Change. |
| Tilidine | 10 g | No Change. |
| Trimeperidine | 2 g | No Change. |
| **Schedule II** | | |
| 1-Phenylcyclohexylamine | 2 g | No Change. |
| 1-Piperdinocyclohexanecarbonitrile | 2 g | 27 g. |
| 4-Anilino-N-phenethyl-4-piperidine (ANPP) | 1,800,000 g | No Change. |
| Alfentanil | 15,000 g | 19,550 g. |
| Alphaprodine | 2 g | No Change. |
| Amobarbital | 40,007 g | No Change. |
| Amphetamine (for conversion) | 8,500,000 g. | |
| Amphetamine (for sale) * | 25,300,000 g | 33,400,000 g. |

| Basic class | Previously established 2012 quotas | Proposed adjusted 2012 quotas |
|---|---|---|
| * DEA has determined that the revised total quantity to provide for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stock is 29,400,000 g. DEA has further determined that an additional 4,000,000 g is necessary to provide for future research and development needs and unexpected emergencies that could affect market availability. | | |
| Carfentanil | 0 g | 5 g. |
| Cocaine | 216,000 g | No Change. |
| Codeine (for conversion) | 65,000,000 g | No Change. |
| Codeine (for sale) | 39,605,000 g | No Change. |
| Dextropropoxyphene | 7 g | No Change. |
| Dihydrocodeine | 400,000 g | No Change. |
| Diphenoxylate | 900,000 g | No Change. |
| Ecgonine | 83,000 g | No Change. |
| Ethylmorphine | 2 g | No Change. |
| Fentanyl | 1,428,000 g | No Change. |
| Glutethimide | 2 g | No Change. |
| Hydrocodone (for sale) | 59,000,000 g | 63,000,000 g. |
| Hydromorphone | 3,455,000 g | 3,628,000 g. |
| Isomethadone | 4 g | No Change. |
| Levo-alphacetylmethadol (LAAM) | 3 g | No Change. |
| Levomethorphan | 5 g | No Change. |
| Levorphanol | 3,600 g | No Change. |
| Lisdexamfetamine | 12,000,000 g | No Change. |
| Meperidine | 5,500,000 g | No Change. |
| Meperidine Intermediate-A | 5 g | No Change. |
| Meperidine Intermediate-B | 9 g | No Change. |
| Meperidine Intermediate-C | 5 g | No Change. |
| Metazocine | 5 g | No Change. |
| Methadone (for sale) | 20,000,000 g | No Change. |
| Methadone Intermediate | 26,000,000 g | No Change. |
| Methamphetamine | 3,130,000 g | No Change. |
| [750,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,331,000 grams for methamphetamine mostly for conversion to a schedule III product; and 49,000 grams for methamphetamine (for sale)] | | |
| Methylphenidate | 56,000,000 g | No Change. |
| Morphine (for conversion) | 83,000,000 g | No Change. |
| Morphine (for sale) | 39,000,000 g | No Change. |
| Nabilone | 20,502 g | No Change. |
| Noroxymorphone (for conversion) | 7,200,000 g | No Change. |
| Noroxymorphone (for sale) | 401,000 g | 1,981,000 g. |
| Opium (powder) | 63,000 g | 73,000 g. |
| Opium (tincture) | 1,000,000 g | No Change. |
| Oripavine | 9,800,000 g | 15,300,000 g. |
| Oxycodone (for conversion) | 5,600,000 g | No Change. |
| Oxycodone (for sale) | 98,000,000 g | 98,700,000 g. |
| Oxymorphone (for conversion) | 12,800,000 g | No Change. |
| Oxymorphone (for sale) | 5,500,000 g | No Change. |
| Pentobarbital | 34,000,000 g | No Change. |
| Phenazocine | 5 g | No Change. |
| Phencyclidine | 24 g | No Change. |
| Phenmetrazine | 2 g | No Change. |
| Phenylacetone | 16,000,000 g | No Change. |
| Racemethorphan | 2 g | No Change. |
| Remifentanil | 2,500 g | No Change. |
| Secobarbital | 336,002 g | No Change. |
| Sufentanil | 5,000 g | No Change. |
| Tapentadol | 5,400,000 g | No Change. |
| Thebaine | 116,000,000 g | No Change. |

Aggregate production quotas for all other schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 remain at zero. Pursuant to 21 CFR part 1303, the Deputy Administrator may adjust the 2012 aggregate production quotas and individual manufacturing quotas allocated for the year.

**Comments**

Pursuant to 21 CFR 1303.11 and 1303.13, any interested person may submit written comments on or objections to these proposed determinations. Based on comments received in response to this Notice, the Deputy Administrator may hold a public hearing on one or more issues raised. In the event the Deputy Administrator decides in his sole discretion to hold such a hearing, the Deputy Administrator will publish a notice of any such hearing in the **Federal Register**. After consideration of any comments and after a hearing, if one is held, the Deputy Administrator will publish in the **Federal Register** a Final

Order determining any adjustment of the aggregate production quota.

Dated: June 28, 2012.

**Michele M. Leonhart,**

*Administrator.*

[FR Doc. 2012–16396 Filed 7–3–12; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF JUSTICE

### Drug Enforcement Administration

### Importer of Controlled Substances; Notice of Application; Myoderm

Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this is notice that on May 9, 2012, Myoderm, 48 East Main Street, Norristown, Pennsylvania 19401, made application to the Drug Enforcement Administration (DEA) for registration as an importer of the following basic classes of controlled substances:

| Drug | Schedule |
|---|---|
| Amphetamine (1100) | II |
| Lisdexamfetamine (1205) | II |
| Methylphenidate (1724) | II |
| Pentobarbital (2270) | II |
| Nabilone (7379) | II |
| Codeine (9050) | II |
| Oxycodone (9143) | II |
| Hydromorphone (9150) | II |
| Hydrocodone (9193) | II |
| Levomethorphan (9210) | II |
| Meperidine (9230) | II |
| Methadone (9250) | II |
| Methadone intermediate (9254) | II |
| Morphine (9300) | II |
| Oxymorphone (9652) | II |
| Fentanyl (9801) | II |

The company plans to import the listed controlled substances in finished dosage form for clinical trials, and research.

The import of the above listed basic classes of controlled substances would be granted only for analytical testing and clinical trials. This authorization does not extend to the import of a finished FDA approved or non-approved dosage form for commercial distribution in the United States.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedule I or II, which fall under the authority of section 1002(a)(2)(B) of the Act 21 U.S.C. 952(a)(2)(B) may, in the circumstances set forth in 21 U.S.C. 958(i), file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47.

Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than August 6, 2012.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, 40 FR 43745–46, all applicants for registration to import a basic class of any controlled substance in schedules I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: June 28, 2012.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2012–16493 Filed 7–3–12; 8:45 am]

**BILLING CODE 4410–09–P**

## DEPARTMENT OF JUSTICE

### National Institute of Corrections

### Solicitation for a Cooperative Agreement—Curricula Review and Revision: NIC Trainer Development Series

**AGENCY:** National Institute of Corrections, U.S. Department of Justice.

**ACTION:** Solicitation for a Cooperative Agreement.

**SUMMARY:** The National Institute of Corrections' (NIC) Academy Division is soliciting proposals from organizations, groups, or individuals to enter into a cooperative agreement for the review, revision, and/or development of competency-based, blended modality training curricula with the aim of providing corrections agencies and professionals with the knowledge, skills, and abilities needed to train and develop their staff.

**DATES:** Application must be received by 4 p.m. (EDT) on Friday, July 20, 2012.

**ADDRESSES:** Mailed applications must be sent to: Director, National Institute of Corrections, 320 First Street NW., Room 5002, Washington, DC 20534.

Applicants are encouraged to use Federal Express, UPS, or similar service to ensure delivery by the due date.

Hand delivered applications should be brought to 500 First Street NW., Washington, DC 20534. At the front desk, dial 7–3106, extension 0 for pickup.

Faxed applications will not be accepted. Electronic applications can be submitted via *http://www.grants.gov.*

**FOR FURTHER INFORMATION CONTACT:** All technical or programmatic questions concerning this announcement should be directed to Michael Guevara, Correctional Program Specialist, National Institute of Corrections. Mr. Guevara can be reached by calling 800–995–6429, ext. 6617, or by email at *mguevar@bop.gov.* In addition to the direct reply, all questions and responses will be posted on NIC's Web site at *www.nicic.gov* for public review (the names of those submitting questions will not be posted). The Web site will be updated regularly and postings will remain on the Web site until the closing date of this cooperative agreement solicitation. Only questions received by 12 p.m. (EDT) on July 13, 2012 will be posted on the NIC Web site.

**SUPPLEMENTARY INFORMATION:**

*Overview:* NIC is revitalizing its trainer development series with the goal of helping corrections agencies and trainers improve staff training and development. NIC is interested in updating some of its curricula, including ''Training Design and Development,'' ''Foundation Skills for Trainers,'' ''Building Agency Success: Developing an Effective FTO/OJT Training Program,'' and ''Training for Training Directors.'' NIC is also interested in the development of a model Training for Trainers template that could be applied broadly, enabling agencies to train trainers in existing curricula.

All curricula will follow the Instructional Theory into Practice (ITIP) model and will incorporate blended learning strategies. A copy of the ''ITIP Toolkit,'' which may be useful in helping awardees develop acceptable curricula, is available on the NIC Web site at *http://nicic.gov/Library/024773.* An essential component of this project will be the incorporation of current research on adult learning and performance. The use of multiple delivery technologies is required.

*Background:* NIC has prioritized capacity building in corrections agencies for decades. While NIC frequently relied on traditional classroom-based training in the past, the emergence of new technologies and the